GYBYS(SH:600332) 2 1 Shi Ji Jing Ji Bao Dao·2026-01-09 10:27Core Insights - The research conducted by Baiyunshan Zhongyi Pharmaceutical has achieved a significant breakthrough in traditional Chinese medicine (TCM) applied to reproductive medicine, with results published in the prestigious journal Nature Communications [1][2] - This study marks the first clinical research results on TCM in reproductive medicine to be featured in Nature Communications, providing a new case for evidence-based research in this field [1] Group 1: Research Details - The clinical trial was a multi-center, prospective, double-blind, placebo-controlled randomized study involving 1,467 women aged 35-42 undergoing fresh embryo transfer via IVF/ICSI [1] - The study found that the Zishen Yutai Pill significantly increased the live birth rate in older women (≥35 years) during fresh embryo transfer cycles, with a relative increase of approximately 23% (RR≈1.23) [2] Group 2: Publication and Impact - The research paper titled "Zishen Yutai Pill increased live births in advanced maternal age women: A randomized clinical trial" has been published online in Nature Communications, which has a high impact factor of 15.7, known for its rigorous academic review [2] - Following the publication of these high-level research results, there have been requests from research and medical institutions in Europe and the United States to conduct joint trials or register the product for sale [2]